Evidence map›Paper›PMID 32725444›Full record

Observational studyEndocrine2020

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly.

Ignacio Bernabéu, Carmen Fajardo, Mónica Marazuela, Fernando Cordido, Eva María Venegas, Pedro de Pablos-Velasco, Gonzalo Piedrola Maroto, María Pilar Olvera, Isabel Pavón de Paz, Davide Carvalho and 3 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Endocrine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02807233 (Observational, Multicenter, Cross-sectional, Observational Study to Evaluate the Effectiveness in Routine Clinical Practice of Lanreotide Autogel 120 mg at Extended Dosing Intervals), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02807233 completednot on this map

Observational, Multicenter, Cross-sectional, Observational Study to Evaluate the Effectiveness in Routine Clinical Practice of Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) for the Treatment of Acromegaly: SOMACROL Study.

TypeobservationalSponsorIpsenRan2016 to 2017Enrolled115ConditionsAcromegaly
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Current controversies in acromegaly care.The Journal of clinical endocrinology and metabolism · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Novel therapies for acromegaly.Endocrine connections · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ignacio BernabéuEndocrinology and Nutrition Department, Hospital Clínico Universitario Santiago de Compostela, Santiago de Compostela, Spain. bernabeumoron@gmail.com.ORCID http://orcid.org/0000-0001-8421-7394
Carmen FajardoEndocrinology and Nutrition Department, Hospital Universitario de La Ribera, Alzira (Valencia), Spain.
Mónica MarazuelaEndocrinology and Nutrition Department, Hospital Universitario La Princesa, Universidad Autónoma Madrid, Instituto Princesa, Madrid, Spain.
Fernando CordidoFaculty of Health Sciences and INIBIC, University of A Coruña, and Endocrinology and Nutrition Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
Eva María VenegasEndocrinology and Nutrition Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Pedro de Pablos-VelascoEndocrinology and Nutrition Department, University of Las Palmas de Gran Canaria. Spain, Las Palmas, Spain.
Gonzalo Piedrola MarotoEndocrinology and Nutrition Departament Hospital Universitario Virgen de las Nieves, Granada, Spain.
María Pilar OlveraEndocrinology and Nutrition Departament, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
Isabel Pavón de PazEndocrinology and Nutrition Departament, Hospital Universitario de Getafe, Madrid, Spain.
Davide CarvalhoDepartment of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário São João, Faculty of Medicine, i3S, Universidade do Porto, Porto, Portugal.
Carme RomeroAdknoma Health Research S.L., Barcelona, Spain.
Guillermo De la CruzIpsen Pharma, Barcelona, Spain.
Cristina Álvarez EscoláEndocrinology and Nutrition Department, Hospital Universitario La Paz, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRecent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effectiveness of lanreotide autogel 120 mg delivered at EDIs (>4 weeks) in routine clinical practice.

methodsCross-sectional, multicentre, observational study conducted to determine the effectiveness-measured by control of serum insulin-like growth factor 1 (IGF-1)-of lanreotide autogel 120 mg at dosing intervals >4 weeks for ≥6 months in selected patients with acromegaly treated in routine clinical practice (NCT02807233). Secondary assessments included control of growth hormone (GH) levels, treatment adherence, patient satisfaction, and quality of life (QoL) using validated questionnaires (EQ-5D, AcroQoL, and TSQM-9). Patients who received radiotherapy within the last 6 months were excluded.

resultsAmong 109 patients evaluated, mean (SD) age was 59.1 (13.2) years. IGF-1 values were normal (mean [SD]: 175.0 [74.5], 95% CI: 160.8 -189.1) in 91.7% of cases and normal in 91.4% of patients without previous radiotherapy treatment (n = 81). GH levels were ≤2.5 and ≤1 ng/mL, respectively, in 80.6% and 58.3%. Most patients were treated either every 5-6 (57.8%) or 7-8 weeks (38.5%), with 2.8% treated greater than every 8 weeks. The mean AcroQoL score was 63.0 (20.1). The mean global treatment satisfaction score (TSQM-9) was 75.1 (16.6). Treatment adherence (defined as no missed injections) was 94.5%.

conclusionLanreotide autogel 120 mg at intervals of >4 weeks provided IGF-1 control in more than 90% of patients with acromegaly. Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in patients who have achieved good biochemical control with long-acting SSAs.

Indexed as

AcromegalyHuman Growth HormoneCross-Sectional StudiesDelayed-Action PreparationsHumansInsulin-Like Growth Factor IMiddle AgedPeptides, CyclicQuality of LifeSomatostatinDelayed-Action PreparationsHuman Growth HormoneInsulin-Like Growth Factor IlanreotidePeptides, CyclicSomatostatinAcromegalyGrowth hormoneInsulin-like growth factor 1LanreotideSomatostatin

Identifiers

PMID32725444
PMCPMC7674328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.